Vollbach, Kristina
Tenbrock, Klaus
Wagner, Nobert
Horneff, Gerd
Klein, Ariane
Foeldvari, Ivan
Haas, Johannes-Peter
Aries, Peer
Gauler, Georg
Striesow, Frank
Hoff, Paula
Scholz, Christine
Tatsis, Stefanie
Seipelt, Eva
Klotsche, Jens
Minden, Kirsten
Funding for this research was provided by:
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
Article History
Received: 17 December 2021
Accepted: 2 December 2022
First Online: 13 December 2022
Declarations
:
: Written informed consent was obtained from the patients (age ≥ 18 years) for participation in JuMBO. JuMBO was approved by the Ethics Committee of Charité University Medicine Berlin. JuMBO is conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: KV: No conflict of interestKT: Advisor Novartis, Pfizer, BMS, research grant support from Novartis and PfizerNW: No conflict of interestGH: Speaking fees and honoraria from Abbvie, Bayer, BMS, Chugai Hexal, MSD, Novartis, Pfizer, Roche, and Swedish Orphan (less than $10,000 each).AK: Honoraria from NovartisIF: Advisor and speaking fee from PfizerJPH: No conflict of interestPA: No conflict of interestGG: Speaking and/or consultant fees from Abbvie, Novartis, Gilead, LillyFS: No conflict of interestPH: Consultant fees, speaking fees, research funding, and/or travel expenses from Pfizer and BiogenCS: No conflict of interestST: Speaking fees and honoraria from Biogen, Pfizer, and AbbvieES: None declaredJK: No conflict of interestKM: Consultant of: GlaxoSmithKline, Sanofi, Speakers bureau: Roche